All In Biotech

Drug Trial Radar · NCT00141960

Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease

YM1170 Phase 2/3 Study: A Double Blind, Placebo Controlled, Group-comparison Study in Patients With Non-erosive Gastroesophageal Reflux Disease

Last checked: Nov 19, 2026Latest source record: Nov 21, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 480 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

480

Actual

Start

Sep 2005

Primary completion

Not stated

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Sep 2, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Gastroesophageal reflux disease (GERD) considered to be associated with mucosal damages in the esophagus and heartburn, which may sometimes interfere with daily activities due likely to reflux of acid gastric contents. While most of the patients given the diagnosis of GERD do not exhibit endoscopically obvious impairment in esophageal mucous membrane, they have subjective symptoms of non-erosive GERD including heartburn. But no drug has been launched in Japan, which targets non-erosive GERD. This study will examine the efficacy and safety of famotidine in subjects with non-erosive GERD.

Conditions

  • Gastroesophageal Reflux

Interventions

  • FamotidineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of days with no heart burn in the treatment period

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Hokkaido Region, Japan

  • Site not named

    Kanto Region, Japan

  • Site not named

    Kinki Region, Japan

  • Site not named

    Kyushu Region, Japan

  • Site not named

    Shikoku Region, Japan

  • Site not named

    Tohoku Region, Japan

  • Site not named

    Tokai Region, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.